Nyhet -

The splendour of tolerogenic cell therapies

The biotech company Idogen develops tolerogenic cell therapies to prevent biological drugs, transplanted organs or the body’s own cells or tissue from being attacked by the patient’s immune system.

Idogen was founded 2008 in Lund, but is today a public company listed on the Nasdaq First North Growth Market. The company has now entered into a very exciting phase where it’s first clinical trial, a phase 1/2a in patients with hemophilia A, will begin in the very soon future. The results from this study will be very interesting, since it will provide data which will be important for future partnership discussions.

Targeting unwanted immunological reactions

The technology behind Idogen’s therapies is based on the immune system’s function to attack foreign cells such as bacteria, infections and viruses, which is a desired reaction.

Unfortunately, there are diseases and conditions that cause the immune system to attack cells and proteins that are supposed to be present in the body, thus causing an unwanted reaction. It is this unwanted reaction that Idogen is targeting with their tolerogenic cell therapy. The aim with the cell therapy is to develop a very specific tolerance for selected antigens.

Next up: clinical trials

The most advanced development program in Idogen’s portfolio is called IDO 8. It is aimed at patients with severe hemophilia A who have developed neutralizing antibodies against their vital treatment with the protein-based coagulation factor VIII.

“We have successfully developed a treatment based on the patient’s own cells that can wean the body into accepting treatment with factor VIII. We have a partnership with a manufacturer in the Netherlands since December 2019, and we are planning to start the first clinical trial in patients within the IDO 8 program very soon”, says Anders Karlsson, CEO of Idogen.

The introduction of a new treatment that can facilitate tolerance for factor VIII treatment with neutralizing antibodies would have a significant impact on treatment of severe hemophilia A patients.

Tolerance in transplantations

Idogen is also developing the tolerogenic cell therapy IDO T, targeting the problem with organ rejection after transplantation. IDO T is developed primarily for kidney transplantation but may be modified to suit transplantation of other organs in the future.

IDO T aims to reduce the need for immunosuppressive drugs and thereby reduce the risk of cancer and infections after transplantation. The ultimate goal with our cell therapy is to extend the life of the transplanted organ”, says Anders Karlsson.

Treating autoimmune diseases

Idogen has also a third development program, aimed at treatment of autoimmune diseases. The development program is called IDO AID, and is in early pre-clinical development.

Patients with autoimmune diseases are often treated for long periods with drugs that severely suppress the immune system. However, the effect against the underlying disease is rarely optimal and the treatment can lead to unwanted side effects. There are for many of these diseases a significant medical need for improved therapies.

“Our tolerogenic cell therapy aims to reduce the need for broad and unspecific immunosuppressive drugs and instead introduce a treatment that specific targets the antigen that triggers the unwanted immune reaction”, says Anders Karlsson.

Idogen is evaluating the potential for IDO AID in a group of autoimmune diseases where there is a significant medical need and where a treatment has the opportunity to be granted orphan drug status.

Relaterade länkar

Ämnen

  • Ekonomi, finans

Kategorier

  • medicon valley life science

Regioner

  • Skåne

Kontakter

Relaterat innehåll

  • Providing a fast lane to preclinical development

    The past year has been very productive at the relatively small Contract Research Organisation (CRO) Redoxis. Being specialised in preclinical drug development and efficacy evaluation models, Redoxis offers invaluable support to any pharmaceutical drug developer at the very early stages.
    “A lot of CROs tend to focus on the later phases of development, even if they still retain a preclinical app

  • Novel treatments for aggressive cancer based on a unique target

    The discovery of the unique target integrin α10β1 may change the outcome of cancer treatment for thousands of patients across the world. Tumor-targeting antibodies for the treatment of aggressive cancers are currently being developed by Targinta, a subsidiary of biopharma company Xintela in Lund.
    Targinta is the oncology subsidiary of the stem cell company Xintela. Both Xintela and Targinta ar

  • Very promising clinical results in new treatment of varicose veins

    Established in 2013 by Dr Michael Åkesson, the company MedVasc was created to help his pursuit on improving the procedure of minimally invasive treatment in the condition of varicose vein. Michael has a long experience in developing and testing new catheters for endovascular techniques.
    The earning potential of Solutio (which was patented in 2015) paved the way for additional investment and cre

  • The Peritus Clinic offers the fastest treatment for prostate cancer

    The Peritus Clinic is located in Lund, to be more precise, on Scheelevägen 8, adjacent to the Medicon Village science park. Patients with different kinds of prostate diseases are welcomed to a modern, world-class hospital with four operating theaters, one of which is equipped with the latest DaVinci robotic surgery platform.
    Peritus’ goal is to establish a clinic at the forefront that gathers

  • A winning team for In Vivo Research Services

    Based in Medicon Village, IVRS (In Vivo Research Services) is a preclinical CRO which provides innovating drug validation studies both in vitro and in vivo allowing to accelerate the drug development process for unmet needs related to severe human diseases.
    IVRS specialises in providing 3D-images with the aim to characterise disease progression; follow the therapeutic effect throughout the comp